Actinium Pharmaceuticals (Delaware) (ATNM) vs GridAI Technologies (GRDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GridAI Technologies (GRDX) has outperformed Actinium Pharmaceuticals (Delaware) (ATNM) over the past year, gaining 20.0% versus a loss of 29.9%. Over five years, ATNM leads with a -86.6% price change compared with -100.0% for GRDX. GridAI Technologies is the larger company by market cap ($35.4 million vs $34.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | GRDX |
|---|---|---|
| Share price | $1.10 | $4.97 |
| Market cap | $34.59M | $35.44M |
| 1-day change | +1.85% | +3.54% |
| YTD return | -20.59% | +3.00% |
| 1-year return | -29.87% | +20.00% |
| 5-year return | -86.57% | -99.99% |
| P/E ratio (TTM) | 3.06 | — |
| EPS (TTM) | $0.36 | $-5.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.74 | $6.93 |
| 52-week low | $0.735 | $1.87 |
| Distance from 52-week high | -36.78% | -28.27% |
| Analyst consensus | none | — |
| Avg. price target upside | +227.27% | — |
| Average volume | 139.78K | 104.68K |
| Shares outstanding | 31.44M | 7.13M |
| Employees | 27 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRDX has outperformed ATNM by 49.9 percentage points over the past year.
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About GridAI Technologies
GRDX stock →GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.
Health Care · Biotechnology: Pharmaceutical Preparations
ATNM vs GRDX FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or GridAI Technologies?
GridAI Technologies (GRDX) is larger, with a market capitalization of $35.44M compared with $34.59M for Actinium Pharmaceuticals (Delaware) (ATNM).
Which stock has performed better over the past year, ATNM or GRDX?
GRDX returned +20.00% over the past 12 months, compared with -29.87% for ATNM (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and GridAI Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.